Research news

A study of patients at UCLH and North Middlesex University Hospital published in The Lancet Infectious Diseases suggests that the B.1.17. variant of Covid-19 is not associated with more severe illness and death, but appears to lead to higher virus load.

The Com-Cov trial in which UCLH is a site looking at alternating vaccines has been expanded to include the Moderna and Novavax vaccines.

Achilles Therapeutics, a company built on research at UCLH, UCL Cancer Institute and the Francis Crick Institute has successfully raised $175.5 million through its initial public offering in the United States.

A front page story and patient case study highlight SUMMIT Study early diagnosis outcomes.

In a major study involving UCLH a third of people who took a new drug for treating obesity lost more than one-fifth of their total body weight.